Inhibitor

(redirected from metalloproteinase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal.
Related to metalloproteinase inhibitor: metalloprotease inhibitor

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha (v) beta (3) receptor blockade.
Marimastat is a matrix metalloproteinase inhibitor and a potential anti-cancer treatment that has been licensed to Schering-Plough Corporation.
Marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer, BB-3644, a follow-on to marimastat, is in Phase I development for cancer, BB-10153 has completed Phase I development for cardiovascular disease; and BB-2827, a collagenase inhibitor for inflammation is in Phase I development.
British Biotech today announced the results of Study 140, a phase III clinical trial of the oral matrix metalloproteinase inhibitor (MMPI), marimastat.
Its lead product, marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer and has been licensed worldwide to Schering Plough Corporation except for Japan and the Far East where it has been licensed to Tanabe Seiyaku Co.
Study 140, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat, in patients with small cell lung cancer, has been completed and the data have been collected.
Matrix Metalloproteinase Inhibitor Prevents Acute Lung Injury After Cardiopulmonary Bypass, Circulation, 1999;100:400-406.
British Biotech (NASDAQ:BBIOY) announces the results of Study 186, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat.
British Biotech announces the results of Study 131, a Phase III clinical trial of the oral matrix metalloproteinase inhibitor, marimastat.
Matrix metalloproteinase inhibitors in rheumatic diseases.

Full browser ?